Ad
related to: panitumumab package insert video
Search results
Results From The WOW.Com Content Network
Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008, for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS". Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.
DailyMed is a website operated by the U.S. National Library of Medicine (NLM) to publish up-to-date and accurate drug labels (also called a "package insert") to health care providers and the general public.
Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer. [4] [5] It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer.
A package insert from 1970, with Ovrette brand contraception pills A package insert is a document included in the package of a medication that provides information about that drug and its use. For prescription medications , the insert is technical , providing information for medical professionals about how to prescribe the drug.
During the first month after Election Day in November, the S&P stock index rose a nifty 5.3%.Investors cheered incoming President Donald Trump, who promised fiscal stimulus in the form of tax cuts ...
Nimotuzumab (h-R3, [2] BIOMAb EGFR, Biocon, India; [3] TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was ...
When Shamrock was born, DeBruler posted TikTok videos featuring the lucky puppy on her account, @living_the_golden_life. Shamrock's social media debut received over 12 million views .
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2]